Key Takeaways The FDA approved Uzedy as once-monthly maintenance therapy for adults with bipolar I disorder.Uzedy sales surged 134% in H1 2025 to $93 million, with full-year sales expected to be around$200 million.The BD-I label expansion is expected to further strengthen Teva's branded drug portfolio.Teva Pharmaceutical Industries Limited (TEVA) recently announced that the FDA has approved expanded use of its branded product, Uzedy (risperidone).The regulatory body has now approved Uzedy (50 mg, 75 mg and ...